Intracranial Collaterals in Acute Stroke and Clinical Outcome

September 8, 2021 updated by: Ahmed Mamdouh Mohammed Tawfeeq, Assiut University

Evaluation of Collateral Vessels in Patients With Acute Ischemic Stroke Receiving Thrombolytic Therapy (Clinical and Radiological Study)

Assessment of the evolution of intracranial collaterals and its relationship with functional outcomes in acute ischemic stroke (AIS) patients treated with IV tissue plasminogen activator (tPA).

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Intracranial collaterals Assessment in acute ischemic stroke In clinical practice, infarct growth does not always progress to involve the full extent of the vascular territory, even if the affected intracranial artery fails to recanalize. The presence and recruitment of various collateral channels are believed to be responsible for this phenomenon in acute ischemic stroke (AIS). These collaterals may also play an important role in influencing the safety and efficacy of acute revascularization approaches. Although blood supply from the leptomeningeal collaterals may temporarily maintain the ischemic penumbra, the persistence and effectiveness of this alternative circulatory supply is erratic and unpredictable. Some collaterals may disappear over time (collateral failure); this is one of the mechanisms responsible for clinical deterioration following initial improvement.

Conversely, dramatic resolution of initial neurologic deficits may be seen though the occluded intracranial artery did not recanalize, often attributable to the rapid improvement of cerebral perfusion via effective collateral pathways (collateral recruitment). Therefore, the temporal behavior of intracranial collaterals may play an important role in determining the functional outcome in AIS patients.

CT angiography (CTA) of the brain is acutely performed in AIS patients before or immediately after administering IV tissue plasminogen activator (tPA) The Alberta Stroke Program Early CT (ASPECTS) leptomeningeal collaterals score on CT-angiography helps in prognosticating functional outcome in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis. Leptomeningeal collaterals in AIS are dynamic, especially during the first few hours or days of AIS.

In animals, 3 different types of collaterals have been identified: transient collaterals that could be seen immediately after the stroke and last less than 90 minutes; impermanent collaterals that disappear after 90-150 minutes; and persistent collaterals, which can be seen for longer periods.

Patients with good collateral flow demonstrated less hypo perfused tissue and less infarct growth within the penumbra zone than those with poor collateral . A relationship is found between good early collaterals on pretreatment imaging and smaller infarct volume with better outcomes.

The initial state of the collateral circulation on the pretreatment CTA also has bearing on the clinical effect of the collateral recruitment on the day 2 CTA.

However, collateral recruitment with poor pretreatment collaterals was associated with poor functional outcome at 3 months and a higher risk of intracranial hemorrhage.

One plausible mechanism that delayed collateral recruitment lead to worse outcomes could be related to the maximal vasodilation in the ischemic area and how collateral recruitment in the adjacent regions may trigger a steal-like phenomenon with resultant expansion of the ischemic core. Another possible mechanism could be related to failed autoregulation in the affected vascular territory, leading to increased hyper perfusion damage with a higher chance of bleeding.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Assiut, Egypt, 71511
        • Assiut University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All patients with acute ischemic stroke within 4.5 hours - legible for receiving IV r TPA- admitted to Neurology department of Asyut University within 1 year (2017-2018)

Description

IInclusion Criteria:

  • Patient presenting to the emergency department with symptoms consistent with ischemic stroke.
  • Age > 18 yrs.
  • Evidence of a visible and symptomatic intracranial occlusion on baseline CT-angiography (intracranial ICA, M1 MCA segment +/- intracranial ICA, proximal M2 MCA).
  • Treatment with IV tPA.

Exclusion Criteria:

  • Intracranial hemorrhage (ICH) identified on baseline CT.
  • Previous moderate to large stroke in the ipsilesional hemisphere.
  • Modified Rankin Scale > 2 at baseline.
  • Unable to have CT-angio performed due to recent estimated creatinine clearance eCCr<60 ml/min, contrast allergy or other reasons.
  • Any terminal illness (patient not expected to survive > 1 year).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients in AIS receiving actilyse
the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
thrombolytic therapy
Other Names:
  • Alteplase

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
90-days functional outcome
Time Frame: 90 days

90-day modified Rankin Score (mRS) 0-2 or equal to the pre-stroke modified Rankin scale he Modified Rankin Scale (mRS) The scale runs from 0-6 0 - No symptoms.

  1. - No significant disability. Able to carry out all usual activities, despite some symptoms.
  2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
  3. - Moderate disability. Requires some help, but able to walk unassisted.
  4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
  5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
  6. - Dead.
90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Early neurologic improvement
Time Frame: 24 hours

Defined as The National Institutes of Health Stroke Scale score "NIHSS" of 0 to 2 at 24 hours or an 8-point drop in NIHSS score from baseline to 24 hours.

The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke

24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Essam Darwish, Professor, Assiut University
  • Study Director: Ahmed Hamdy, Ass.Prof, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 23, 2017

Primary Completion (Actual)

January 1, 2021

Study Completion (Actual)

August 1, 2021

Study Registration Dates

First Submitted

October 2, 2017

First Submitted That Met QC Criteria

October 13, 2017

First Posted (Actual)

October 17, 2017

Study Record Updates

Last Update Posted (Actual)

September 16, 2021

Last Update Submitted That Met QC Criteria

September 8, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • Collaterals and acute stroke

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Collateral Circulation, Any Site

Clinical Trials on Actilyse

Subscribe